Refine
Has Fulltext
- yes (1384)
Is part of the Bibliography
- yes (1384)
Year of publication
Document Type
- Journal article (1384) (remove)
Keywords
- Biochemie (80)
- Physiologische Chemie (48)
- Biologie (30)
- biodiversity (23)
- evolution (20)
- gene expression (17)
- cancer (15)
- Cytologie (14)
- foraging (14)
- Apis mellifera (13)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (1384) (remove)
Sonstige beteiligte Institutionen
- Mildred-Scheel-Nachwuchszentrum (2)
- Ökologische Station Fabrikschleichach (2)
- Core Unit Systemmedizin (1)
- DNA Analytics Core Facility, Biocenter, University of Wuerzburg, Wuerzburg, Germany (1)
- DNA Analytics Core Facility, Biocenter, University of Würzburg, Würzburg, Germany (1)
- Department of Animal Ecology and Tropical Biology, University of Würzburg, Würzburg, Germany (1)
- EMBL, Structural and Computational Biology Unit, Heidelberg, Germany (1)
- Forschungsstation Fabrikschleichach (1)
- Fraunhofer Institute Interfacial Engineering and Biotechnology (IGB) (1)
- IZKF (Interdisziplinäres Zentrum für Klinische Forschung), Universität Würzburg (1)
ResearcherID
- D-1221-2009 (1)
Formation of the Aurora-A–MYCN complex increases levels of the oncogenic transcription factor MYCN in neuroblastoma cells by abrogating its degradation through the ubiquitin proteasome system. While some small-molecule inhibitors of Aurora-A were shown to destabilize MYCN, clinical trials have not been satisfactory to date. MYCN itself is considered to be `undruggable' due to its large intrinsically disordered regions. Targeting the Aurora-A–MYCN complex rather than Aurora-A or MYCN alone will open new possibilities for drug development and screening campaigns. To overcome the challenges that a ternary system composed of Aurora-A, MYCN and a small molecule entails, a covalently cross-linked construct of the Aurora-A–MYCN complex was designed, expressed and characterized, thus enabling screening and design campaigns to identify selective binders.